Grin Therapeutics Closes $140M Series D Financing
Here’s a structured list based on the provided information about Grin Therapeutics, Inc.:
Company:
- Startup: Grin Therapeutics, Inc.
- Location: New York City (NYC)
Funding Details:
- Funding Round: Series D Financing
- Amount Raised: $140 million
- Date: 28/05/2025
Investors:
- Angelini Pharma
- Investment: $65 million (strategic equity investment)
- Blackstone Life Sciences
- Investment: $75 million (existing investor)
Founders and Key Personnel:
- Leader: Bruce Leuchter, MD (President & CEO of Neurvati Neurosciences and Grin Therapeutics)
- Additional Key Personnel: Jacopo Andreose, PhD (CEO of Angelini Pharma, joining the Board of Directors)
Overview of Product:
- Investigational Drug: Radiprodil
- Target: Treatment for serious neurodevelopmental disorders including GRIN-NDD and other rare genetic epilepsies.
Collaborations:
- Partnership with Angelini Pharma for development and commercialization outside North America.
Additional Financial Details:
- Upfront Payment: $50 million from Angelini Pharma.
- Milestone Payments: Potential for up to $520 million based on development, regulatory, and sales milestones.
- Royalties: Tiered royalties based on global sales and future sublicense transactions outside of Europe.
Clinical Information:
- Phase: Global pivotal Phase 3 clinical trial expected to start in Q3 of 2025.
- Ongoing Study: Open-label Phase 1b/2a study (Astroscape trial) for radiprodil in specific patient populations.
This breakdown highlights key points regarding Grin Therapeutics’ funding and operational strategy.
Source link
2025-05-28 16:40:20